- Home
- CZNC vs PGEN Comparison
CZNC vs PGEN Comparison
Compare CZNC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- PGEN
- Stock Information
- Founded
- CZNC 1864
- PGEN 1998
- Country
- CZNC United States
- PGEN United States
- Employees
- CZNC N/A
- PGEN N/A
- Industry
- CZNC Major Banks
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- PGEN Health Care
- Exchange
- CZNC Nasdaq
- PGEN Nasdaq
- Market Cap
- CZNC 287.4M
- PGEN 404.4M
- IPO Year
- CZNC N/A
- PGEN N/A
- Fundamental
- Price
- CZNC $19.75
- PGEN $1.62
- Analyst Decision
- CZNC
- PGEN Strong Buy
- Analyst Count
- CZNC 0
- PGEN 3
- Target Price
- CZNC N/A
- PGEN $6.00
- AVG Volume (30 Days)
- CZNC 37.5K
- PGEN 2.0M
- Earning Date
- CZNC 08-06-2025
- PGEN 08-13-2025
- Dividend Yield
- CZNC 5.67%
- PGEN N/A
- EPS Growth
- CZNC 15.34
- PGEN N/A
- EPS
- CZNC 1.75
- PGEN N/A
- Revenue
- CZNC $108,114,000.00
- PGEN $4,201,000.00
- Revenue This Year
- CZNC $6.78
- PGEN $158.57
- Revenue Next Year
- CZNC $4.59
- PGEN $1,086.91
- P/E Ratio
- CZNC $11.30
- PGEN N/A
- Revenue Growth
- CZNC 5.33
- PGEN N/A
- 52 Week Low
- CZNC $16.73
- PGEN $0.65
- 52 Week High
- CZNC $22.68
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- CZNC 62.19
- PGEN 63.16
- Support Level
- CZNC $18.88
- PGEN $1.39
- Resistance Level
- CZNC $19.85
- PGEN $1.70
- Average True Range (ATR)
- CZNC 0.46
- PGEN 0.10
- MACD
- CZNC 0.15
- PGEN 0.01
- Stochastic Oscillator
- CZNC 93.75
- PGEN 75.00
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.